Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) — Cash Flow Reinvestment Rate

Latest as of December 2024: 7.80x

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has a Cash Flow Reinvestment Rate of 7.80x as of December 2024, reinvesting CN¥187.51 Million (capex CN¥187.14 Million plus investments CN¥369.80K) from operating cash flow of CN¥24.04 Million. Check earnings quality score of Hunan Dajiaweikang Pharmaceutical Indust to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

7.80x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥187.51 Million
Capex + Investments

Operating Cash Flow

CN¥24.04 Million
CNY

Capital Expenditures

CN¥187.14 Million
CNY

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Cash Flow Reinvestment Rate (2019–2024)

Historical reinvestment intensity for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd across 3 annual periods. Explore Hunan Dajiaweikang Pharmaceutical Indust debt service capacity to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2024)

Year-by-year capital reinvestment analysis for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd. For live market cap and broader valuation context, see 301126 market cap.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 7.80x CN¥187.51 Million CN¥24.04 Million CN¥187.14 Million ▼ -9.7%
2023 8.64x CN¥234.43 Million CN¥27.13 Million CN¥226.70 Million ▲ +1706.6%
2019 0.48x CN¥65.01 Million CN¥135.91 Million CN¥32.50 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow